The most-read coverage of the latest updates in acute myeloid leukemia (AML) for 2025 focused on the evolution of targeted ...
The American Society of Hematology/ASH 2025 meeting included AML results from AAML1831, MyeChild01, BIG-1, and PALG-AML1/2016 studies.
AML (acute myeloid leukemia) remains a deadly, hard-to-treat disease. Agios has AG-221 in a Phase 3 trial for AML. ImmunoGen has IMGN779 in a Phase 1 trial for AML. FDA approval would likely lead to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback